novartis ag-reg (NOT:Xetra)
Transactions by NOVARTIS AG-REG (NOT) in the last 6 months
Intellia Therapeutics announced that it has received $15 million in its first round of funding co-led by new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.
bioCSL Inc. entered into a definitive agreement to acquire influenza vaccines business from Novartis AG (SWX:NOVN) for approximately $280 million on October 26, 2014. The Novartis influenza vaccines unit will be combined with bioCSL. For the year ended December 31, 2013, influenza vaccines business posted sales of $527 million. The transaction requires regulatory approvals and is expected to close in the second half of 2015. Tim Duncan of Hintons & Associates acted as ...
Raze Therapeutics announced that it has received $24 million in its series A round of funding on October 14, 2014. The transaction included participation from new investors, Atlas Venture L.P., MPM Capital, Merck Serono S.A., Investment Arm, Partners Innovation Fund, Astellas Venture Management LLC, and Novartis AG. As part of the round, Ansbert Gadicke of MPM Capital, Nilesh Kumar of Merck Serono S.A., Investment Arm, Reza Halse of Partners Innovation Fund, Jason Rhodes ...
Atlas Venture L.P.
Merck Serono S.A., Investment Arm
Partners Innovation Fund
Seventh Sense Biosystems, Inc. announced that it will receive $16,467,084 in funding on July 28, 2014. The company will issue common shares, convertible debt and an option, warrant or other right to acquire another security in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. As of August 8, 2014, the company has received $10,467,084 in its first tranche close from eight investors.
Laboratory Corp. of America Holdings
Siemens Financial Services, Inc.
dievini Hopp BioTech holding GmbH & Co. KG entered into an agreement to acquire additional 67% stake in LTS Lohmann Therapie-Systeme AG from BWK GmbH Unternehmensbeteiligungsgesellschaft and Novartis AG (SWX:NOVN) on July 16, 2014. The minority shareholders will receive an equivalent offer from dievini Hopp. LTS Lohmann Therapie-Systeme AG reported an annual turnover of more than €300 million.
The transaction is subject to regulatory approvals, other customary conditions ...
|Gilead Sciences Inc||$96.98 USD||+3.19|
|Merck & Co Inc||$57.79 USD||+0.005|
|Pfizer Inc||$31.47 USD||-0.1801|
|Procter & Gamble Co/The||$92.86 USD||-0.60|
|View Industry Companies|